VRTX · Earnings call · 2026Q3T · Full report

Povetacicept Regulatory Review

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 20 · Surprise 24

Vertex said the agency has been involved in reviewing povetacicept, and the company is nearing the end of the review. Management said all data have been submitted, including an entire module on CMC and manufacturing, and that regulators have had the data for a long time. Vertex filed toward the end of March 2026 and said it is having the expected discussions with the agency. The CEO said she feels good about the filing, including its manufacturing content.

Key facts

• Vertex completed a filing for potential accelerated povetacicept approval in Saudi Arabia, where the drug received breakthrough status; the company estimated an incremental 7,000-patient opportunity there.
• Vertex planned povetacicept's IgAN PDUFA date for November 30, 2026.
• Vertex planned povetacicept submissions in Europe and Asia after study completion and availability of two-year eGFR data.
• Vertex planned to complete povetacicept's trial through its originally designed two-year eGFR follow-up to support a global launch ambition.
• Vertex submitted all data for povetacicept, including an entire CMC and manufacturing module, and said it was nearing the end of the review.
• Vertex filed povetacicept toward the end of March 2026.
• Vertex said the FDA was comfortable with one-year GFR data, while other regulators had different expectations, supporting its plan to obtain full two-year data.
• In povetacicept's program, more than 500 people were studied and IgG was measured every four weeks; there were no opportunistic infections, and serious infection adverse events were 0.5% in both povetacicept and placebo groups.